NASONEX

This brand name is authorized in Austria, Brazil, Canada, Germany, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Japan, Lithuania, Malta, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, United Kingdom, United States, South Africa

Active ingredients

The drug NASONEX contains one active pharmaceutical ingredient (API):

1 Mometasone
UNII MTW0WEG809 - MOMETASONE FUROATE MONOHYDRATE

Mometasone is a topical glucocorticoid with local anti-inflammatory properties. It is likely that much of the mechanism for the effects of mometasone lies in its ability to inhibit the release of mediators of the inflammatory cascade.

Read about Mometasone

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
NASONEX Nasal Spray, Suspension Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
NASONEX Nasal spray FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
R01AD09 Mometasone R Respiratory system → R01 Nasal preparations → R01A Decongestants and other nasal preparations for topical use → R01AD Corticosteroids
Discover more medicines within R01AD09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 527315120017617, 527315120017717
Country: CA Health Products and Food Branch Identifier(s): 02238465
Country: DE Bundesinstitut für Arzneimittel und Medizinprodukte Identifier(s): 00055509, 02193150, 05049548, 05120832, 10663256
Country: EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria Identifier(s): 22.376-1-08-05
Country: EE Ravimiamet Identifier(s): 1028966, 1726501, 1726512, 1726523, 1820135, 1820168, 1823554, 1823587
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 61905, BE190854, BE190854IP
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 474551, 474643
Country: FR Base de données publique des médicaments Identifier(s): 63566855
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 139359, 143237, 26794
Country: HK Department of Health Drug Office Identifier(s): 43556
Country: HR Agencija za lijekove i medicinske proizvode Identifier(s): HR-H-032470068
Country: IE Health Products Regulatory Authority Identifier(s): 31587, 35235, 67120, 67145
Country: JP 医薬品医療機器総合機構 Identifier(s): 1329710Q1027, 1329710Q2023
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1003843, 1068854, 1077869, 1077870, 1079727, 1081256, 1082883, 1085547, 1085569, 1089255, 1089256
Country: MT Medicines Authority Identifier(s): MA031/01901, PI770/10401A, PI908/12702A
Country: NL Z-Index G-Standaard Identifier(s): 14269961
Country: NL Z-Index G-Standaard, PRK Identifier(s): 52434
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 7958
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100080562, 100157980, 100346267, 100351831, 100355964, 100363923, 100370544, 100384078, 100386634, 100460850, 100467170
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W68334001, W68334002, W68334003, W68334004
Country: SG Health Sciences Authority Identifier(s): 10763P
Country: TN Direction de la Pharmacie et du Médicament Identifier(s): 6523111
Country: US FDA, National Drug Code Identifier(s): 0085-1288
Country: ZA Health Products Regulatory Authority Identifier(s): 32/21.5.1/0157, 36/21.5.1/0414

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.